SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that it will host a conference call and live webcast at 5:00 p.m. Eastern Time on Tuesday, February 19, 2008 to discuss the Company's fourth quarter and year end 2007 financial results. A press release will be issued before the U.S. stock markets open that morning.
A live audio webcast of management's presentation will be available on the Investor Relations section of the Company's web site at http://www.favrille.com. Alternatively, callers may participate in the conference call by dialing (888) 713-4213 or (617) 213-4865, passcode 19388148. To pre-register for this call, please go to https://www.theconferencingservice.com/prereg/key.process?key=P9YHNKNHB. Callers who pre-register will be given a unique PIN to gain immediate access to the call and bypass the live operator. You may pre-register at any time, including up to and after the call start time. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 99385491.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the
development and commercialization of targeted immunotherapies for the
treatment of cancer and other diseases of the immune system. The Company's
lead product candidate, Specifid(TM) (formerly FavId(R)), is based upon
unique genetic information extracted from a patient's tumor. Specifid is
currently under investigation in a pivotal Phase 3 clinical trial for
patients with follicular B-cell non- Hodgkin's lymphoma (NHL) and Phase 2
clinical trials in other B-cell NHL indications. The Company is developing
additional applications based on its immunotherapy expertise and
proprietary cost-effective manufacturing technology, including a second
product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.
Pete De Spain
Director, Investor Relations
& Corporate Communications
|SOURCE Favrille, Inc.|
Copyright©2008 PR Newswire.
All rights reserved